Entera Bio Ltd
NASDAQ:ENTX
Entera Bio Ltd
Revenue
Entera Bio Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Entera Bio Ltd
NASDAQ:ENTX
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Revenue
$11m
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
NASDAQ:KMDA
|
Revenue
$142.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Revenue
$4.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Revenue
$82.7m
|
CAGR 3-Years
91%
|
CAGR 5-Years
136%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Revenue
₪0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Entera Bio Ltd's Revenue?
Revenue
0
USD
Based on the financial report for Dec 31, 2023, Entera Bio Ltd's Revenue amounts to 0 USD.